Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Aprepitant
Drug ID BADD_D00157
Description Aprepitant, an antiemetic, is a substance P/neurokinin 1 (NK1) receptor antagonist which, in combination with other antiemetic agents, is indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy. Aprepitant is a selective high-affinity antagonist of human substance P/neurokinin 1 (NK1) receptors. Aprepitant has little or no affinity for serotonin (5-HT3), dopamine, and corticosteroid receptors, the targets of existing therapies for chemotherapy-induced nausea and vomiting (CI NV).
Indications and Usage For the prevention of nausea and vomiting associated with highly emetogenic cancer chemotherapy, including high-dose cisplatin (in combination with other antiemetic agents).
Marketing Status approved; investigational
ATC Code A04AD12
DrugBank ID DB00673
KEGG ID D02968
MeSH ID D000077608
PubChem ID 135413536
NDC Product Code 50370-0048; 59285-015; 66039-851; 73005-0009; 47426-201; 68462-112; 55111-892; 56125-634; 65085-0043; 66039-880; 13668-593; 0006-0461; 0006-3066; 0006-3862; 47426-401; 13612-0024; 50370-0022; 68462-584; 68462-585; 56125-632; 64567-0021; 0006-0464; 68462-583; 0781-2321; 0781-2322; 0781-2323; 56125-633; 73309-380; 0781-4063; 0006-0462; 50370-0038; 65372-1169; 13668-591; 13668-592; 65977-0024; 72643-020; 13668-594
Synonyms Aprepitant | MK 869 | MK 0869 | MK-0869 | MK0869 | MK-869 | MK869 | (2R)-(1R)-3,5-bis(Trifluoromethylphenyl)ethoxy)-(3S)-(4-fluoro)phenyl-4-(3-(5-oxo-1H,4H-1,2,4-triazole)methyl-morpholine | MK 0517 | MK0517 | MK-0517 | (1-(3,5-bis(Trifluoromethyl)phenyl)ethoxy)-3-(fluoro)phenyl-4-(3-oxo-1,2,4-triazol-5-yl)methylmorpholine | Emend | L 754030 | L-754030 | L754030 | L 754,030 | L-754,030 | L754,030
Chemical Information
Molecular Formula C23H21F7N4O3
CAS Registry Number 170729-80-3
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal discomfort07.01.06.001--Not Available
Abdominal distension07.01.04.001--
Abdominal pain07.01.05.0020.000081%
Abdominal pain upper07.01.05.003--
Acne23.02.01.001--Not Available
Alanine aminotransferase increased13.03.04.005--
Altered state of consciousness19.07.01.003; Available
Anaphylactic reaction24.06.03.006;
Anaphylactic shock24.06.02.004; Available
Angioedema22.04.02.008;; Available
Aspartate aminotransferase increased13.03.04.011--
Asthenia08.01.01.0010.000121%Not Available
Back pain15.03.04.0050.000121%
Blood albumin decreased13.09.01.001--Not Available
Blood bilirubin increased13.03.04.018--
Blood creatine increased13.13.01.001--Not Available
Blood creatinine increased13.13.01.004--
Blood glucose increased13.02.02.002--Not Available
Blood potassium decreased13.11.01.010--Not Available
Blood pressure decreased13.14.03.002--Not Available
Blood pressure increased13.14.03.005--Not Available
Blood urea increased13.13.01.006--Not Available
Blood urine13.13.02.011--Not Available
Body temperature decreased13.15.01.010--Not Available
Body temperature increased13.15.01.001--Not Available
Bradycardia02.03.02.002--Not Available
The 1th Page    1 2 3 4 5    Next   Last    Total 9 Pages
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene